ReviewGut microbes2017
Stable core virome despite variable microbiome after fecal transfer.
Review in Gut microbes, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 79 citations in OpenAlex.
- Trial
- The mycobiome, virome and archaeome in gastrointestinal cancers: molecular pathogenesis and therapeutic intervention.Molecular cancer · 2026Review
- Review
- Metagenomic analysis of the human gut virome reveals functional signatures and viral stability across hospitalized and non-hospitalized diarrheal and non-diarrheal individuals.Gut pathogens · 2026Article
- Species-level virome profiling reveals compositional differences in the gut prokaryotic DNA virome of people with HIV-1 on antiretroviral therapy.Gut microbes reports · 2026Article
- Use of proximity ligation shotgun metagenomics to investigate the dynamics of plasmids and bacteriophages in the gut microbiome following fecal microbiota transplantation.Gut microbes · 2025Article
- Commensal Viruses Promote Intestinal Stem Cell Regeneration Following Radiation Damage by Inhibiting Hyperactivation of RIG-I and Notch Signals.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Gut Virome and Aging: Phage-Driven Microbial Stability and Immune Modulation.Aging and disease · 2025Review
- The gut virome in association with the bacteriome in gastrointestinal diseases and beyond: roles, mechanisms, and clinical applications.Precision clinical medicine · 2025Review
- Gut virome and its implications in the pathogenesis and therapeutics of inflammatory bowel disease.BMC medicine · 2025Review
- Antibiotic-perturbed microbiota and the role of probiotics.Nature reviews. Gastroenterology & hepatology · 2025Review
- Reproducible chemostat cultures to minimize eukaryotic viruses from fecal transplant material.iScience · 2024Article
- Overcoming donor variability and risks associated with fecal microbiota transplants through bacteriophage-mediated treatments.Microbiome · 2024Article
- Bacteriophages: a double-edged sword in the gastrointestinal tract.Frontiers in microbiomes · 2024Review
- The Next Generation Fecal Microbiota Transplantation: To Transplant Bacteria or Virome.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Review
- Review
- The impact of storage buffer and storage conditions on fecal samples for bacteriophage infectivity and metavirome analyses.Microbiome · 2023Article
- Emerging applications of phage therapy and fecal virome transplantation for treatment of Clostridioides difficile infection: challenges and perspectives.Gut pathogens · 2023Review
- The Novel Role of Phage Particles in Chronic Liver Diseases.Microorganisms · 2023Review
- The human gut virome: composition, colonization, interactions, and impacts on human health.Frontiers in microbiology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We recently described the 4.5-year time course of the enteric bacterial microbiota and virome of a patient cured from recurrent Clostridium difficile infection (rCDI) by fecal microbiota transplantation (FMT). Here, we extended the virome analyses and found the patient's phage population to exhibit highly donor-similar characteristics following FMT, which remained stable for the whole period tested (up to 7 months). Moreover, the detected viral populations of donor and patient exhibited comparable diversity and richness. These findings were unexpected since enteric viromes are normally highly variable, assumed to influence the bacterial host community and change with environmental conditions. In contrast to the virome, the bacterial microbiota varied indeed for more than 7 months with ongoing dysbiosis before it reached donor similarity. Our findings that are based on sequence information and protein domain analysis seem to suggest that stable phage properties correlate with successful FMT better than the changing bacterial communities. We speculate that we here preferentially detected a stable core virome, which dominated over a variable flexible virome that may have been too heterogeneous for experimental detection or was underrepresented in the databases. It will be interesting to analyze whether the enteric virome allows predictions for the clinical outcome of FMT for rCDI and other diseases such as inflammatory bowel disease or obesity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.